# AstraZeneca: Phase 3 study in Epithelial Ovarian Cancer (950 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer |
| NCT ID | NCT07851025 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Epithelial Ovarian Cancer |
| Intervention types | drug |
| Target enrollment | 950 |
| Site countries | United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Germany, Greece, India |
| Posted | 2026-10-01 |
| Planned start | 2026-09-16 |
| Event | Newly registered study |
| Event date | 2026-10-01 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 950 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07851025). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.